- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06293469
Accelerated Flap Coverage in Severe Lower Extremity Trauma (FLAP ATTACK)
Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.
The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.
The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lily Mundy, MD
- Phone Number: 410-706-2492
- Email: LMundy3@jhu.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
The inclusion criteria are:
- Patients 18 years of age or older.
- Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
- Will have all planned musculoskeletal injury surgeries performed by a participating surgeon or delegate.
- Able to be randomized within 48 hours of injury.
- Site anticipates being able to implement the accelerated flap protocol due to temporary local logistics.
The exclusion criteria are:
- Primary amputation anticipated prior to attempted flap for management of the injury.
- Critical limb ischemia that requires re-vascularization for limb perfusion.
- Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
- Burns at the musculoskeletal injury site.
- Incarceration.
- Currently enrolled in a trial that does not permit co-enrollment.
- Declined to provide informed consent.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because a legally authorized representative was unavailable.
- Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
- Prior enrollment in the trial.
- Other reason to exclude the patient, as approved by the Methods Centre.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Accelerated Flap Coverage
Accelerated flap surgery timing at a goal of within 72 hours from injury.
Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.
|
Timing of the flap surgery is with a goal of 72 hours from injury
|
Active Comparator: Standard of Care Flap Timing
The flap surgery will be performed at the standard of care timing for the institution.
Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.
|
Timing of the flap surgery is the standard of care flap timing for the participating institution.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical status
Time Frame: 6 months
|
Clinical status is a hierarchical composite of the following outcomes:
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 6 months and 12 months
|
All-cause mortality
|
6 months and 12 months
|
Amputation
Time Frame: 6 months and 12 months
|
Amputation related to injury.
Amputation will be time-to-event, with the assumption that earlier is worse than later.
|
6 months and 12 months
|
Unplanned re-operation
Time Frame: 6 months and 12 months
|
Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure).
Re-operation for infection and flap complication will be time-to-event, with the assumption that earlier is worse than later.
Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse.
|
6 months and 12 months
|
Number of days in hospital
Time Frame: 6 months and 12 months
|
Days in an acute in-patient hospital (i.e., not rehab or nursing facility)
|
6 months and 12 months
|
Quality of life as assessed by the Limb-Q
Time Frame: 6 months and 12 months
|
Health-related quality of life and patient satisfaction measured with the Limb-Q.
The Limb-Q is a set of independently functioning scales.
All scales are scored 0-100 (higher = better).
The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used.
|
6 months and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lily Mundy, MD, Johns Hopkins School of Medicine
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00434587
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Tibia Fracture
-
Assiut UniversityUnknownOpen Fracture of Tibia
-
Assiut UniversityNot yet recruiting
-
University of California, San FranciscoNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsRecruiting
-
University of California, San FranciscoNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedOpen Tibia FractureTanzania
-
Major Extremity Trauma Research ConsortiumUnited States Department of DefenseCompletedSevere Open Fractures of the Tibia (Shin) BoneUnited States
-
University of California, San FranciscoDoris Duke Charitable Foundation; Wyss Foundation, IncCompletedTrauma | Tibial Fractures | Open Fracture of Tibia
-
Assiut UniversityNot yet recruitingOpen tíbia Fracture
-
Second Affiliated Hospital, School of Medicine,...The First People's Hospital of Huzhou; Taizhou Hospital; Ningbo No.2 HospitalNot yet recruiting
-
Wake Forest University Health SciencesOrthopaedic Trauma Association; Orthopaedic Research and Education FundCompletedType II and IIa Open Tibia FracturesUnited States
-
Brett D. CristTerminatedGustilo-Anderson Type III Open Tibia FractureUnited States
Clinical Trials on Accelerated Flap Coverage Surgery
-
University of LouisvilleCompletedRecession, GingivalUnited States
-
Arab American University (Palestine)Completed
-
University of Sao PauloGeistlich Pharma AGCompletedGingival Recession, GeneralizedBrazil
-
University of Sao PauloCompleted
-
University of Sao PauloCompleted
-
Cairo UniversityNot yet recruitingGingival Recession | Recession, Gingival | Thin-gingivaEgypt
-
Cairo UniversityCompletedPosterior Cross BiteEgypt
-
University of ParmaRecruiting
-
McMaster UniversityHamilton Health Sciences Corporation; Population Health Research InstituteCompletedHip FracturesCanada, United Kingdom, South Africa, Netherlands, Italy, India, Pakistan, China, Belgium, France, United States, Spain, Colombia, Hong Kong, Malaysia, Poland, Thailand
-
Karadeniz Technical UniversityCompleted